Does telomere length mediate associations between inbreeding and increased risk for bipolar I disorder and schizophrenia?

Mansour, Hader; Chowdari, Kodavali V.; Fathi, Warda; Elassy, Mai; Ibrahim, Ibtihal; Wood, Joel; Bamne, Mikhil; Tobar, Salwa; Yassin, Amal; Salah, Hala; Elsayed, Hanan; Eissa, Ahmed; El-Boraie, Hala; Ibrahim, Nahed E.; Elsayed, Mahmoud; El-Bahaei, Wafaa; Gomaa, Zeinab; El-Chennawi, Farha; Nimgaonkar, Vishwajit L.

doi:10.1016/j.psychres.2011.01.010

Cited by 53 publications

(37 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Shorter telomere length in a sample of moderately depressed BD patients seemed not to be influenced by medication, although a decreased mean telomere length was observed in drug-free patients when Shortened telomeres in bipolar disorder compared to controls. 15 In contrast, Mansour et al 16 reported no difference in telomere length between BD patients and a healthy control group. Multiple mechanisms might be implicated in telomere shortening in BD, including oxidative stress 28 leading to secondary DNA damage, 29 inflammation, 30 and glucocorticoid load.…”

Section: Discussionmentioning

confidence: 96%

“…15 These findings have not been replicated in other studies that showed no changes in telomere length (measured as the T/S ratio) in subjects with BD or schizophrenia. 16 Hoen et al 17 found that anxiety disorders were strongly associated with telomere shortening after 2 years of follow-up, while no prospective correlation was observed in patients with major depression. More recently, Garcia-Rizo et al 18 reported significantly decreased telomere length in newly diagnosed, antidepressant-naïve patients with depression compared to controls.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease

Barbé-Tuana

Parisi

Panizzutti

et al. 2016

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: Bipolar disorder (BD) has been associated with increased rates of age-related diseases, such as type II diabetes, metabolic syndrome, osteoporosis, and cardiovascular disorders. Several biological findings have been associated with age-related disorders, including increased oxidative stress, inflammation, and telomere shortening. The objective of this study was to compare telomere length among participants with BD at early and late stages and age-and gender-matched healthy controls. Methods: Twenty-six euthymic subjects with BD and 34 healthy controls were recruited. Genomic DNA was extracted from peripheral blood and mean telomere length was measured using real-time quantitative polymerase chain reaction. Results: Telomere length was significantly shorter in both the early and late subgroups of BD subjects when compared to the respective controls (p = 0.002 and p = 0.005, respectively). The sample size prevented additional subgroup analyses, including potential effects of medication, smoking status, and lifestyle. Conclusion: This study is concordant with previous evidence of telomere shortening in BD, in both early and late stages of the disorder, and supports the notion of accelerated aging in BD.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease

Barbé-Tuana

Parisi

Panizzutti

et al. 2016

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…However, one large study reported longer LTL in schizophrenia than in HCs (Nieratschker et al, 2013). Yet other studies have detected no difference in LTL between individuals with schizophrenia and HCs (Li et al, 2015;Malaspina et al, 2014;Mansour et al, 2011). Reasons for discrepancies in findings among these studies are not known, but may include inadequate sample sizes, differing gender distributions, quality of diagnostic evaluations, nature of the comparison sample, chronicity and severity of illness, medical illnesses, medication history, and history of treatment responsiveness, along with demographic and lifestyle factors such as age, diet, body-mass index (BMI), exercise, and tobacco use.…”

Section: Introductionmentioning

confidence: 90%

Leukocyte telomere length: Effects of schizophrenia, age, and gender

Wolkowitz

Jeste

Martin

et al. 2017

Journal of Psychiatric Research

View full text Add to dashboard Cite

a b s t r a c tBackground: Schizophrenia is linked with early medical comorbidity and mortality. These observations indicate possible "accelerated biological aging" in schizophrenia, although prior findings are mixed, and few such studies have examined the role of gender. One putative marker of biological aging is leukocyte telomere length (LTL), which typically shortens with age. Methods: We assessed LTL in phenotypically well characterized 134 individuals with schizophrenia (60 women and 74 men) and 123 healthy comparison subjects (HCs) (66 women and 57 men), aged 26 to 65 years. Results: Overall, LTL was inversely associated with age (t(249) ¼ -6.2, p < 0.001), and a gender effect on the rate of LTL decrease with age was found (t(249) ¼ 2.20, p ¼ 0.029), with men declining more rapidly than women. No significant overall effect of diagnosis on the rate of decline was detected. However, at the average sample age (48 years), there was a significant gender effect in both schizophrenia and HC groups (t(249) ¼ 2.48, p ¼ 0.014), with women having longer LTL than men, and a significant gender X diagnosis effect (t(249) ¼ 2.43, p ¼ 0.016) -at the average sample age, women with schizophrenia had shorter LTL than HC women. Discussion: Gender, not the diagnosis of schizophrenia, was the major factor involved with LTL shortening across the age range studied. We discuss the constraints of a cross-sectional design and other methodological issues, and indicate future directions. Understanding the impact of schizophrenia on biological aging will require separate evaluations in men and women.Published by Elsevier Ltd.

show abstract

“…22,[53][54][55][56][57][58][59][60][61][62][63] Most studies investigated a mixed-age sample of adults, 2 included only older participants. 55,58 All reviewed studies had at least one comparison group: 34 compared schizophrenia patients to a nonpsychiatric HC group; 4 involved at least one psychiatric comparison group in addition to an HC group; 32,53,61,63 one included only psychiatric comparison groups 40 ; one compared subtypes of patients with schizophrenia. 34 The reviewed articles examined a variety of different biomarkers, including markers of inflammation (26%), TL (24%), indices of oxidative stress (17%), gene expression/regulation (10%), metabolic/vascular function (10%), receptor/synaptic function (10%), testosterone (2%), and brain-derived neurotropic factor (BDNF) (2%).…”

Section: Review Processmentioning

confidence: 99%

Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions

Nguyen

Eyler

Jeste

2017

Schizophrenia Bulletin

105

View full text Add to dashboard Cite

Background: Schizophrenia is associated with increased physical morbidity and early mortality, suggesting that the aging process may be accelerated in schizophrenia. However, the biological underpinnings of these alterations in aging in schizophrenia are unclear. Method: We conducted a detailed search of peer-reviewed empirical studies to evaluate evidence for accelerated biological aging in schizophrenia based on systemic, age-related biomarkers. We included studies that investigated differences between persons with schizophrenia and healthy comparison subjects in levels of biomarkers known to be associated with aging and examined the relationship of these biomarkers to age in the 2 groups. Results: Forty-two articles that met our selection criteria were reviewed. Nearly 75% reported abnormal biomarker levels among individuals with schizophrenia, including indices of inflammation, cytotoxicity, oxidative stress, metabolic health, gene expression, and receptor/synaptic function, with medium to large effect sizes reported in many studies. Twenty-nine percent of the studies observed differential age-related decline in schizophrenia. Markers of receptor/synaptic function and gene expression were most frequently differentially related to age in schizophrenia. Schizophrenia patients with greater disease severity and longer illness duration exhibited higher levels of inflammatory and oxidative stress biomarkers and shorter telomere length. Conclusions: Most studies show biomarker abnormalities in schizophrenia, and there is some suggestion for accelerated aging. Although definitive interpretation is limited by cross-sectional design of the published reports, findings in the area of gene expression and synaptic function are promising and pave the way for future longitudinal studies needed to fully test this hypothesis.

show abstract

Does telomere length mediate associations between inbreeding and increased risk for bipolar I disorder and schizophrenia?

Cited by 53 publications

References 35 publications

Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease

Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease

Leukocyte telomere length: Effects of schizophrenia, age, and gender

Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions

Contact Info

Product

Resources

About